January 26, 2012 - CML - Updates from the American Society of Hematology (ASH®) Annual Meeting
Date: January 26, 2012
Time: 1:00 p.m. - 2:00 p.m. ET
Read: CML News Links | Transcript | Transcript (Spanish)
Download: Program Slides | Program Slides (Spanish)
Listen: Presentation | Q&A Session | Presentation/Q&A Session (Spanish)
Access: Virtual Lecture
- Current treatment options for CML patients
- Emerging therapies for CML treatment
- The role of clinical trials in the advancement of CML treatment
- Quality of life issues in the treatment of patients with CML
David L. Porter, MD
Professor of Medicine
Director, Blood and Marrow Transplantation
Hospital of the University of Pennsylvania
Questions Asked by the CML Community
- If a patient is on imatinib (Gleevec®), having no side effects and has reached a major molecular response (MMR), is there any reason to switch to nilotinib (Tasigna®) or dastinib (Sprycel®)?
- If a patient already reached MMR, how often should he/she be seeing a doctor and how often is the BCR-ABL test done?
- What studies are being done to understand toxicity over time, when changing therapy from Gleevec to Sprycel to Tasigna?
- How likely is it that a patient's pleural effusion was caused by Sprycel?
- Is there any research being done on younger patients with CML and the effects of treatment on fertility?
- Can you address fertility concerns for men taking Gleevec?
- Are dark spots on the skin and rashes side effects of Gleevec?
- What information do you have on treatment for children with CML?
- What are the long-term effects of Gleevec in children?
- What is the standard treatment or recommendation from a physician's standpoint for women that become pregnant while on Gleevec?
- Can you discuss a CML vaccine that would eliminate continuing everyday dosage?
- Should a patient consider changing to one of the newer drugs if he or she takes a reduced dose of Gleevec?
- In general, what percentage of patients need to be switched from Gleevec to Sprycel or Tasigna for side effects?